252 related articles for article (PubMed ID: 22407480)
21. Marc Kirschner. Interview by Asher Mullard.
Kirschner M
Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
[No Abstract] [Full Text] [Related]
22. Menelas Pangalos. Interview by Asher Mullard.
Mullard A
Nat Rev Drug Discov; 2013 Jun; 12(6):418. PubMed ID: 23722338
[No Abstract] [Full Text] [Related]
23. Traditional drug-discovery model ripe for reform.
Cressey D
Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
[No Abstract] [Full Text] [Related]
24. An audience with...John Reed.
Reed J; Mullard A
Nat Rev Drug Discov; 2014 Mar; 13(3):170-1. PubMed ID: 24577393
[No Abstract] [Full Text] [Related]
25. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Bouzom F; Ball K; Perdaems N; Walther B
Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
[TBL] [Abstract][Full Text] [Related]
26. Open partnering of integrated drug discovery: continuing evolution of the pharmaceutical model.
Hutchins S; Torphy T; Muller C
Drug Discov Today; 2011 Apr; 16(7-8):281-3. PubMed ID: 21335101
[No Abstract] [Full Text] [Related]
27. Where Are the Nanodrugs? An Industry Perspective on Development of Drug Products Containing Nanomaterials.
Havel HA
AAPS J; 2016 Nov; 18(6):1351-1353. PubMed ID: 27520380
[TBL] [Abstract][Full Text] [Related]
28. To make better therapeutics, companies strive to increase the content of results and get them faster.
Szpir M
Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
[No Abstract] [Full Text] [Related]
29. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA; Ungell AL; Dolgos H
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
[TBL] [Abstract][Full Text] [Related]
30. Trial watch: personalized medicines in late-stage development.
Milne CP; Garafalo S; Bryan C; McKiernan M
Nat Rev Drug Discov; 2014 May; 13(5):324-5. PubMed ID: 24781541
[No Abstract] [Full Text] [Related]
31. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
[No Abstract] [Full Text] [Related]
32. Vas Narasimhan.
Narasimhan V; Mullard A
Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275
[No Abstract] [Full Text] [Related]
33. Application of PBPK modelling in drug discovery and development at Pfizer.
Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
[TBL] [Abstract][Full Text] [Related]
34. Interview with Lisa Shipley. Interviewed by Lisa Parks.
Shipley L
Bioanalysis; 2013 Aug; 5(15):1819-20. PubMed ID: 23905854
[TBL] [Abstract][Full Text] [Related]
35. Network biology as a new approach to drug discovery.
Lowe JA; Jones P; Wilson DM
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):524-6. PubMed ID: 20812143
[TBL] [Abstract][Full Text] [Related]
36. An audience with Patrick Vallance.
Vallance P
Nat Rev Drug Discov; 2010 Nov; 9(11):834. PubMed ID: 21030993
[No Abstract] [Full Text] [Related]
37. Translational regenerative medicine research: essential to discovery and outcome.
Mason C; Dunnill P
Regen Med; 2007 May; 2(3):227-9. PubMed ID: 17511558
[No Abstract] [Full Text] [Related]
38. Q&A: Bernard Munos.
Bender E
Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
[No Abstract] [Full Text] [Related]
39. Ian Tomlinson.
Tomlinson I
Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183
[No Abstract] [Full Text] [Related]
40. PBPK as a tool in regulatory review.
Huang SM
Biopharm Drug Dispos; 2012 Mar; 33(2):51-2. PubMed ID: 22351604
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
